BIOHARVEST SCIENCES INC - CNVCF STOCK NEWS

Welcome to our dedicated page for BIOHARVEST SCIENCES news (Ticker: CNVCF), a resource for investors and traders seeking the latest updates and insights on BIOHARVEST SCIENCES stock.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a pioneering biotechnology company with a focus on Botanical Synthesis. The company leverages its patented technology platform to produce plant-based molecules without the need to grow the underlying plant. BioHarvest is actively engaged in developing science-based and clinically proven therapeutic solutions in nutraceutical health and wellness products, including dietary supplements, and the creation of plant cell-based Active Pharmaceutical Ingredients (APIs) for specific medical indications. With a strong emphasis on innovation and research, BioHarvest aims to revolutionize the health and wellness industry with its cutting-edge products.

08/30/2023 08:00 AM

News

BioHarvest Sciences Reports Q2 2023 Results Demonstrating Continued Growth Momentum

Rhea-AI Summary

BioHarvest Sciences Inc announces Q2 2023 results with revenues of USD 2.75M, representing 228% YoY growth and 27% QoQ growth. VINIA total active subscriber count grew by 620%. Gross product margins increased to 40% in Q2 2023. Cost of customer acquisition declined by 62% compared to Q2 2022. Net loss per share was USD 0.6. Cash flow break even targeted in late 2023, profitability in early 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.85%

Tags

08/24/2023 08:40 AM

News

BioHarvest Sciences to Host Virtual Shareholder Presentation September 6, 2023

Rhea-AI Summary

BioHarvest Sciences Inc. announces Q2 Performance Update Presentation on September 6, 2023, CEO to discuss Q2 financials and provide information on major marketing programs and new product pipeline.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

07/18/2023 08:00 AM

News

BioHarvest Sciences Inc. Announces Closing of Private Placement of Convertible Notes

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.65%

Tags

06/30/2023 08:27 AM

News

BioHarvest Chief Medical Officer Shares Personal Journey at Collision Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/27/2023 08:00 AM

News

BioHarvest Sciences Chief Medical Officer to Speak at Collision Conference in Toronto

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.45%

Tags

06/26/2023 09:21 AM

News

BioHarvest Participates at Major Jefferies Investment Conference Tuesday June 27

Rhea-AI Summary

BioHarvest Sciences Inc. will be participating in the Jefferies Vitamins and Supplements Conference in London, England. CEO Ilan Sobel will be speaking on a panel about emerging and disruptive brands. The conference brings together investors and major corporations.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.33%

Tags

06/21/2023 08:00 AM

News

BioHarvest Unveils New Consumption Categories for its Flagship Product VINIA

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.43%

Tags

06/06/2023 08:00 AM

News

BioHarvest Sciences Adds Renowned Scientist to Scientific Advisory Board

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.9%

Tags

05/31/2023 07:30 AM

News

BioHarvest Reports Q1 2023 Results Demonstrating Strong Year Over Year Growth

Rhea-AI Summary

BioHarvest Sciences Inc. (BHSC) has reported its Q1 2023 results, with revenues for its flagship product VINIA® reaching USD 2.2M, representing a growth of 209% compared to the same quarter last year. The company is reiterating its revenue guidance of USD 17M+ for the year and aims to achieve cash flow break-even by Q4 2023. Gross margins have improved to 37% in Q1 2023, compared to 26% in Q1 2022, demonstrating an improvement of 42%. The company plans to introduce new products, such as VINIA® Functional Coffee, by the end of the year.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.35%

Tags

10/05/2021 08:08 AM

News

BioHarvest Sciences Inc. Reports Strong Q3 2021 Results on all of the Company's Activities

Rhea-AI Summary

BioHarvest Sciences Inc. (CSE: BHSC) announced strong Q3 2021 results, reporting VINIA® sales of USD 688K, a 44% increase from Q2 and a remarkable 1,198% growth compared to Q3 2020. In Israel, sales orders reached USD 452K, while USD 236K came from the U.S. pilot program, marking 251% growth over Q2. The company is preparing to launch a new manufacturing facility in Israel to meet increasing demand. Financing activities raised USD 3.48M through private placements and USD 4.41M from warrants, supporting its growth initiatives.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.69%

Tags

FAQ

What is the current stock price of BIOHARVEST SCIENCES (CNVCF)?

The current stock price of BIOHARVEST SCIENCES (CNVCF) is $5.99 as of October 14, 2024.

What is the market cap of BIOHARVEST SCIENCES (CNVCF)?

The market cap of BIOHARVEST SCIENCES (CNVCF) is approximately 109.9M.

What is the core business of BioHarvest Sciences Inc.?

BioHarvest Sciences Inc. focuses on Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules.

What are the main products of BioHarvest Sciences Inc.?

The company specializes in nutraceutical health and wellness products, including dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs).

What is BioHarvest Sciences Inc.'s approach to therapeutic solutions?

BioHarvest Sciences Inc. is committed to developing science-based and clinically proven therapeutic solutions using innovative botanical synthesis technology.

What are some recent achievements of BioHarvest Sciences Inc.?

Recent achievements include strong revenue growth, margin optimization, the launch of a Contract Development and Manufacturing Organization (CDMO) Services Business Unit, and signing contracts with notable pharmaceutical and food nutrition industry players.

What are BioHarvest Sciences Inc.'s future growth plans?

BioHarvest Sciences Inc. aims to achieve EBITDA break even in the second half of 2024, secure an uplisting to the Nasdaq Stock Market, and continue delivering shareholder value through product innovation and business expansion.